Atrial fibrillation through the years: contemporary evaluation and management.

Information about a real patient is presented in stages (boldface type) to an expert clinician (Dr Valentin Fuster), who responds to the information, sharing his reasoning with the reader (regular type). A discussion by the authors follows. A 61-year-old man presents with 2 weeks of exertional dyspnea. Pertinent medical history includes hypertension, nephrolithiasis, and internal hemorrhoids. He takes no medications and has no known drug allergies. His father died after a myocardial infarction at 57 years of age. He formerly smoked 1 pack of cigarettes daily for 15 years but ceased tobacco use 10 years before presentation. He ingests 2 glasses of alcohol weekly and denies illicit drug use. His caffeine intake is limited. He is an architect and is married, with healthy children. On physical examination, his temperature is 98.0°F, blood pressure is 130/85 mm Hg bilaterally, pulse is irregular at 130 beats per minute, and respiratory rate is 18 breaths per minute with an oxygen saturation of 97% while breathing room air. He is a slender white man in no distress. His jugular venous pressure is elevated at 14 cm H 2 O. There is no thyromegaly, and the carotid upstrokes are brisk, without bruits. Cardiovascular examination reveals a rapid and irregular heart rhythm with variation in the intensity of the first heart sound. The point of maximal impulse is not displaced. The remainder of the chest and abdominal examination is within normal limits. The extremities are warm and show mild pitting edema. Laboratory testing is significant for normal renal function and electrolytes, but a hemogram reveals a mild thrombocytopenia of 90 000 platelets/μL. ECG demonstrates atrial fibrillation (AF) with an average ventricular rate of 123 bpm ( Figure 1 ). Figure 1. The 12-lead ECG showing atrial fibrillation with a rapid ventricular rate. Dr Valentin Fuster : This is a …

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  G. Lip,et al.  Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation , 2012, Circulation. Arrhythmia and electrophysiology.

[4]  J. Dimarco,et al.  Management of Atrial Fibrillation in Patients With Structural Heart Disease , 2012, Circulation.

[5]  J. Burkhardt,et al.  Examining the safety of amiodarone , 2012, Expert opinion on drug safety.

[6]  C. Polanczyk,et al.  Very Low Risk of Thromboembolic Events in Patients Undergoing Successful Catheter Ablation of Atrial Fibrillation With a CHADS2 Score ⩽3: A Long-Term Outcome Study , 2011, Circulation. Arrhythmia and electrophysiology.

[7]  R. Hunter,et al.  Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death , 2011, Heart.

[8]  David O. Martin,et al.  Natural History and Long-Term Outcomes of Ablated Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.

[9]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[10]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[11]  G. Lip,et al.  Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort , 2010, Stroke.

[12]  A. Chockalingam,et al.  Tachycardia-Induced Cardiomyopathy : Evaluation and Therapeutic Options , 2010 .

[13]  S. Themistoclakis,et al.  The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. , 2010, Journal of the American College of Cardiology.

[14]  Burr Hall,et al.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[15]  J. Brachmann,et al.  Catheter Ablation versus Standard Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE‐AF) ‐ Study Design , 2009, Pacing and clinical electrophysiology : PACE.

[16]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[17]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[18]  H. Collard,et al.  A practical guide for clinicians who treat patients with amiodarone: 2007. , 2007, Heart rhythm.

[19]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[20]  Gianni Tognoni,et al.  Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). , 2005, American heart journal.

[21]  Prashanthan Sanders,et al.  Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.

[22]  Christopher Piorkowski,et al.  Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. , 2004, Heart rhythm.

[23]  M. Domanski,et al.  Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study , 2004, Circulation.

[24]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[25]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[26]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[27]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[28]  G. Kay,et al.  Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. , 2000, Mayo Clinic proceedings.

[29]  B. Lewis,et al.  Identifying patients at high risk for restenosis after percutaneous transluminal coronary angioplasty for unstable angina pectoris. , 1989, The American journal of cardiology.

[30]  A. Wear CIRCULATION , 1964, The Lancet.

[31]  José Jalife,et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation , 2012, Heart rhythm.

[32]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[33]  S. Mouly,et al.  Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. , 2007, The Cochrane database of systematic reviews.

[34]  A. Waldo Radiofrequency Ablation vs Antiarrhythmic Drugs as First-line Treatment of Symptomatic Atrial Fibrillation: A Randomized Trial , 2006 .

[35]  Wolters Kluwer,et al.  Hrs/ehra/ecas Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: a Report of the Heart Rhythm Society (hrs) Task Force , 2022 .